Looking for knowledgable commentary on this development in the coronary stent world.
Bard Previews First Bifurcated Coronary Stent
MURRAY HILL, N.J.--(BUSINESS WIRE)--December 15, 1997--C.R. Bard, Inc. (NYSE-BCR) announced that at the Fourth Thoraxcenter Course on Coronary Stenting held in Rotterdam, the Netherlands, on December 10, Bard previewed its first bifurcated version of the Bard XT stent during a special workshop. Interventional cardiologists had the opportunity to see this unique one-piece Y-shaped stent implanted in a patient during one of the cases transmitted live via satellite during the course.
The modular zig-zag design of the Bard XT stent has proved extremely versatile in clinical use since it affords easy, accurate placement and excellent trackability without compromising radial strength. The design and structure of the stent allow easy access to side branches, and many Bard XT stent users have already achieved good results in bifurcate lesions with two stents placed using the ``kissing balloon'' technique. The availability of a true bifurcated stent with a dedicated ``trouser'' balloon delivery system will make treatment much simpler.
Professor Patrick W. Serruys, M.D., director of the Thoraxcenter Course in Rotterdam, commented, ``The innovative bifurcate stent design and delivery system from Bard bring a new level of convenience to bifurcate stenting, which has traditionally been a complex and time-consuming procedure for the interventional cardiologist. We would expect that, by improving wall coverage in the bifurcate area, an integral concept such as this will provide better long-term clinical outcomes, although further studies are obviously required.''
William H. Longfield, chairman and chief executive officer of C. R. Bard, Inc., said, ``The Bard XT stent is gaining recognition for its versatility and positive clinical results. The level of acceptance of the recent European launch of the premounted XT stent, the enthusiasm being shown by clinicians during our US clinical trial, and the excitement surrounding our new bifurcate stent design are all indications of Bard's commitment to the stent market and the strength of our research and development program.''
Don't see much interest in this novelty item long term. The Bard XT is just an ok stent anyway and leave it to Bard to screw it up royally. (look at what has happened to USCI). They want to use this PR to try to keep them in the stent race...i don't think they have even started their clinical trials yet...